Newsletter - June 2025

EDITORIAL BY PATRICK ALEXANDRE,

FOUNDER & CEO

In this month of June, we are finalizing the delivery of the last batches required to document our application for U.S. market approval of ZEPIZURE®. We felt it was an appropriate time to highlight our Specialty Pharma model, emphasizing our focus on the United States.

Indeed, while BARDA* is urging us more than ever to maintain our pace, it is in the name of this unchanged reality:

ZENEO® can save the lives of American citizens in the event of an attack.
No alternative solution has been developed in the United States.

This confidence, along with the technical and financial support that comes with it, enables us to start producing commercial batches of ZEPIZURE®.

How does our specialty pharma operate?

Interview with Tony TIPTON, COO USA

How does CROSSJECT decide which drugs to develop utilizing the ZENEO® technology?

Our product selection process is firmly grounded in providing solutions for unmet medical needs where ZENEO®’s needle-free delivery offers a true clinical and practical advantages.

CROSSJECT relies on this guiding principle to refine its strategy, which incorporates a balanced short- and long-term revenue plan. This approach ensures both revenue growth and the strengthening of the company’s value, while making a significant contribution to the medical community.

Our objective is to focus on merging clinical lifecycle planning and revenue lifecycle planning by better synergizing the work of Research & Development (R&D), Business Development & Licensing (BD&L) and Commercialization planning.

Olivier LACOMBE, Director of Pharmaceutical Development

NEWS

ZEPIZURE® Junior: the Solution for Pediatric Epileptic Seizures

CROSSJECT is progressing in the development of its pediatric version of ZEPIZURE®. The company completed an echography clinical study allowing to determine and validate the targeted depth of injection in children as compared to adults.

The success of this study confirms the high flexibility of the ZENEO® platform.

Learn more

New Module for the ZENEO® Factory

CROSSJECT developed the ZENEO® Nest, a groundbreaking new module to improve batch aseptic filling of the proprietary glass drug container of the ZENEO® device.

The implementation of this innovation, planned for 2025, is a strategic step in anticipation of the broad deployment of ZEPIZURE® and of its other pipeline product candidates.

Learn more

RESI Conference in Boston

Tony TIPTON, Don ZINN, and Henri BODEAU attended the RESI Conference (Redefining Every Stage of Investment), a key event held during Biotech Week Boston.
The CROSSJECT team met with representatives from the U.S. federal administration, investors, and international companies.

www.crossject.com

CROSSJECT

newsletter@crossject.com

You received this email because you subscribed to our newsletter.

Unsubscribe